Search

Displaying results 2471 - 2480 of 7706 in total
  1. Drug

    Anatibant

    go.drugbank.com/drugs/DB05038
    Experimental

    Anatibant is a selective, very potent, small-molecule Bradykinin B2 receptor antagonist. It is developed for the for the treatment of traumatic brain injury (TBI).

  2. Drug

    Pacritinib

    go.drugbank.com/drugs/DB11697
    ApprovedInvestigational

    Pacritinib is an inhibitor of both wild-type and mutant (V617F) JAK2, as well as FMS-like tyrosine kinase 3 (FLT3), which was granted accelerated approval by the FDA in February 2022 for the treatment … [L40793] The underlying cause of primary MF is unknown, but secondary MF can arise in patients with a history of polycythemia vera or essential thrombocythemia.

  3. Drug

    Pholcodine

    go.drugbank.com/drugs/DB09209
    ApprovedIllicit

    Pholcodine formula is 3-o-morpholinoethylmorphine and it is classified as an antitussive which is defined as an opioid cough suppressant.

  4. Drug

    Abemaciclib

    go.drugbank.com/drugs/DB12001
    ApprovedInvestigational

    On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative advanced or metastatic breast cancer that has progressed … Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity

  5. Drug

    Dipyrithione

    go.drugbank.com/drugs/DB11327
    Approved

    [L2611] It is currently used as a pesticide, and not used in any FDA approved drug products. … [A32829] Interestingly, dipyrithione has been studied and shown to have cytotoxic and potent broad-spectrum antitumor activity, which suggests a potential basis for an anticancer drug development.

  6. Drug

    Icotrokinra

    go.drugbank.com/drugs/DB21724
    ApprovedInvestigational

    [L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108]

  7. Drug

    Isocarboxazid

    go.drugbank.com/drugs/DB01247
    Approved

    [T115] It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription drug on July 1st, 1959.

  8. Drug

    Fosaprepitant

    go.drugbank.com/drugs/DB06717
    ApprovedInvestigational

    Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant.

  9. Drug

    Inositol nicotinate

    go.drugbank.com/drugs/DB08949
    ApprovedWithdrawn

    Nicotinic acid plays an essential role in many important metabolic processes and has been used as lipid-lowering agent.

  10. Drug

    Pirenzepine

    go.drugbank.com/drugs/DB00670
    ApprovedWithdrawn

    It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. … An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function